MARATTO

review · American Journal of Chemistry and Pharmacy

Adverse Drug Reactions in Nigeria’s Geriatric Population and its Prevalence, Etiologies, Implications: A Systematic Review

2024Open access

Abstract

Adverse drug reactions (ADRs) are a significant public health concern. Although the prevalence of ADRs in the general adult population in Nigeria has been studied and documented, there is limited research on ADRs among the geriatric population. This study conducted a systematic review of existing research to determine the prevalence, etiologies and implications of ADRs among Nigerian geriatric population. A comprehensive search was undertaken using PubMed, ResearchGate, and Google Scholar databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline was used for reporting this systematic review. Six studies met the eligibility criteria for inclusion in this review. The prevalence of ADRs among the geriatrics ranged from 4.4% to 31.1%. The gastrointestinal system was the most commonly affected system, with non-steroidal anti-inflammatory drugs (NSAIDs) being the most frequently implicated class of drugs contributing to ADRs. The prevalence of ADRs in the Nigerian geriatric population is underreported. There are insufficient policies and healthcare personnel specialized in caring for geriatric patients. Strategies should be implemented to reduce the incidence of ADRs among geriatric patients.

Research topics

  • Pharmaceutical Practices and Patient Outcomes
  • Pharmacovigilance and Adverse Drug Reactions
  • Pharmaceutical studies and practices

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.54536/ajcp.v3i1.3197

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.